Prognomix Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 9

Prognomix General Information

Description

Developer of diagnostic and predictive technology designed to target type 2 diabetic subjects by using genomic signatures. The company's technology focuses on the discovery and clinical application of genomic signatures predictive of susceptibility to diseases, enabling physicians to predict their complications and individual therapeutic responsiveness.

Contact Information

Website
prognomix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4101, rue Molson
  • Bureau 201
  • Montreal, Quebec H1Y 3L1
  • Canada
+1 (514)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Corporate Office
  • 4101, rue Molson
  • Bureau 201
  • Montreal, Quebec H1Y 3L1
  • Canada
+1 (514)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Prognomix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private 01-Apr-2021 Completed Generating Revenue
2. Grant 01-Jan-2014 Completed Generating Revenue
1. Early Stage VC 29-Mar-2007 $4.1M $4.1M Completed Startup
To view Prognomix’s complete valuation and funding history, request access »

Prognomix Patents

  • 13

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Prognomix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2655665-A1 Single nucleotide polymorphisms and genes associated with t2d-related complications Inactive 21-Dec-2010
US-20140023635-A1 Single nucleotide polymorphisms and genes associated with t2d-related complications Inactive 21-Dec-2010
EP-2655665-A4 Single nucleotide polymorphisms and genes associated with t2d-related complications Inactive 21-Dec-2010
EP-2619308-A2 Genes linking several complications of type-2 diabetes (t2d) Inactive 20-Sep-2010
US-20120134981-A1 Genes linking several complications of type-2 diabetes (t2d) Inactive 20-Sep-2010 C12Q1/6883
To view Prognomix’s complete patent history, request access »

Prognomix Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Canadian Institutes of Health Research Asset Manager
Génome Québec Government
National Immune Monitoring Laboratory Corporation
National Research Council Canada Government
BDC Capital Growth/Expansion Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Prognomix FAQs

  • When was Prognomix founded?

    Prognomix was founded in 2005.

  • Where is Prognomix headquartered?

    Prognomix is headquartered in Montreal, Canada.

  • What industry is Prognomix in?

    Prognomix’s primary industry is Biotechnology.

  • Is Prognomix a private or public company?

    Prognomix is a Private company.

  • What is Prognomix’s current revenue?

    The current revenue for Prognomix is .

  • How much funding has Prognomix raised over time?

    Prognomix has raised $4.1M.

  • Who are Prognomix’s investors?

    Canadian Institutes of Health Research, Génome Québec, National Immune Monitoring Laboratory, National Research Council Canada, and BDC Capital are 5 of 9 investors who have invested in Prognomix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »